Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9624800.0Aexternal-prioritypatent/GB9624800D0/en
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Publication of NZ336321ApublicationCriticalpatent/NZ336321A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Use of a compound of Formula (I) as a medicament for preventing invasive breast cancer. The medicament may be administered at a concentration of 30-200mg/day, preferably 60mg/day.
NZ336321A1996-10-301999-06-16Use of benzothiophene (raloxifene) for treating breast cancer
NZ336321A
(en)
Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment